What’s the current market cap for 4D Molecular Therapeutics stock?

4D Molecular Therapeutics (FDMT) has a market cap of $663m as of July 04, 2026.

What is the P/E ratio for 4D Molecular Therapeutics stock?

The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of July 04, 2026.

Does 4D Molecular Therapeutics stock pay dividends?

No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of July 04, 2026.

When is the next 4D Molecular Therapeutics dividend payment date?

4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.

What is the beta indicator for 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) has a beta rating of 2.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy 4D Molecular Therapeutics stock | $FDMT Share Price

13:30

15:10

16:45

18:25

20:00

About 4D Molecular Therapeutics

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Ticker

$FDMT

Sector

Health

Primary listing

NASDAQ

Employees

196

Headquarters

EmeryVille, United States

Website

www.4dmoleculartherapeutics.com

FDMT Metrics

BasicAdvanced

$663m

-$2.64

2.76

What the Analysts think about FDMT

Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.

Bulls say / Bears say

4FRONT-1 global Phase 3 trial enrollment completed in March 2026 with 523 patients randomized ahead of schedule, underscoring strong investigator and patient enthusiasm for 4D-150. (GlobeNewswire)

Cash, cash equivalents and marketable securities of $457.6 million as of March 31, 2026 provide funding into the second half of 2028, reducing near-term financing risk. (GlobeNewswire)

Analysts maintain a consensus ‘Buy’ and an average 12-month price target of $28.22, implying over 140% upside to the current share price. (StockAnalysis.com)

Net loss widened to $68.8 million in Q1 2026 (–$1.01 per share) from $48.0 million (–$0.86 per share) in Q1 2025, reflecting accelerated R&D spend on late-stage trials. (GlobeNewswire)

Enrollment completion for 4FRONT-2 is not expected until H2 2026, pushing topline data for the second Phase 3 wet AMD trial into H2 2027 and delaying potential regulatory filings. (GlobeNewswire)

Evercore ISI cut its price target to $23 from $45 while trimming valuation assumptions, highlighting lingering concerns over trial execution and near-term value. (StockAnalysis.com)

Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2026.

FDMT Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

FDMT Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

4FRONT-1 global Phase 3 trial enrollment completed in March 2026 with 523 patients randomized ahead of schedule, underscoring strong investigator and patient enthusiasm for 4D-150. (GlobeNewswire)

Cash, cash equivalents and marketable securities of $457.6 million as of March 31, 2026 provide funding into the second half of 2028, reducing near-term financing risk. (GlobeNewswire)

Analysts maintain a consensus ‘Buy’ and an average 12-month price target of $28.22, implying over 140% upside to the current share price. (StockAnalysis.com)

Net loss widened to $68.8 million in Q1 2026 (–$1.01 per share) from $48.0 million (–$0.86 per share) in Q1 2025, reflecting accelerated R&D spend on late-stage trials. (GlobeNewswire)

Enrollment completion for 4FRONT-2 is not expected until H2 2026, pushing topline data for the second Phase 3 wet AMD trial into H2 2027 and delaying potential regulatory filings. (GlobeNewswire)

Evercore ISI cut its price target to $23 from $45 while trimming valuation assumptions, highlighting lingering concerns over trial execution and near-term value. (StockAnalysis.com)

Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2026.

About 4D Molecular Therapeutics

Ticker

Employees

FDMT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about FDMT

Analyst Ratings

Bulls say / Bears say

FDMT Financial Performance

Income Statement

FDMT Earnings Performance

Earnings per share (EPS)

FDMT News

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

Buy $FDMT

Lightyear

Legal

Work with us

Bulls say / Bears say

4D Molecular Therapeutics/$FDMT

About 4D Molecular Therapeutics

Ticker

Employees

FDMT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about FDMT

Analyst Ratings

Bulls say / Bears say

FDMT Financial Performance

Income Statement

FDMT Earnings Performance

Earnings per share (EPS)

FDMT News

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

What’s the current market cap for 4D Molecular Therapeutics stock?

What is the P/E ratio for 4D Molecular Therapeutics stock?

Does 4D Molecular Therapeutics stock pay dividends?

When is the next 4D Molecular Therapeutics dividend payment date?

What is the beta indicator for 4D Molecular Therapeutics?

Bulls say / Bears say